MCP-1 Predicts Recurrent Cardiovascular Events in Patients with Persistent Inflammation

• Published in: Journal of clinical medicine Vol. 10; no. 5; p. 1137
• Main Authors: Blanco-Colio, Luis M, Méndez-Barbero, Nerea, Pello Lázaro, Ana María, Aceña, Álvaro, Tarín, Nieves, Cristóbal, Carmen, Martínez-Milla, Juan, González-Lorenzo, Óscar, Martín-Ventura, José Luis, Huelmos, Ana, Gutiérrez-Landaluce, Carlos, López-Castillo, Marta, Kallmeyer, Andrea, Cánovas, Ester, Alonso, Joaquín, López Bescós, Lorenzo, Egido, Jesús, Lorenzo, Óscar, Tuñón, José
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 09.03.2021; MDPI
• Subjects: Acute coronary syndromes; Atherosclerosis; Biomarkers; C-reactive protein; Cardiovascular disease; Clinical medicine; Coronary vessels; Heart attacks; Heart failure; Inflammation; Insulin; MCP-1; NT-proBNP; Plasma; Statins; MCP-1; C-reactive protein; NT-proBNP; inflammation
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm10051137

Clinical data indicate that patients with C-reactive protein (CRP) levels higher than 2 mg per liter suffer from persistent inflammation, which is associated with high risk of cardiovascular disease (CVD). We determined whether a panel of biomarkers associated with CVD could predict recurrent events in patients with low or persistent inflammation and coronary artery disease (CAD). We followed 917 patients with CAD (median 4.59 ± 2.39 years), assessing CRP, galectin-3, monocyte chemoattractant protein-1 (MCP-1), N-terminal fragment of brain natriuretic peptide (NT-proBNP) and troponin-I plasma levels. The primary outcome was the combination of cardiovascular events (acute coronary syndrome, stroke or transient ischemic event, heart failure or death). Patients with persistent inflammation ( = 343) showed higher NT-proBNP and MCP-1 plasma levels compared to patients with CRP < 2 mg/L. Neither MCP-1 nor NT-proBNP was associated with primary outcome in patients with CRP < 2 mg/L. However, NT-proBNP and MCP-1 plasma levels were associated with increased risk of the primary outcome in patients with persistent inflammation. When patients were divided by type of event, MCP-1 was associated with an increased risk of acute ischemic events. A significant interaction between MCP-1 and persistent inflammation was found (synergy index: 6.17 (4.39-7.95)). In conclusion, MCP-1 plasma concentration is associated with recurrent cardiovascular events in patients with persistent inflammation.